Phase II study of ‘high-dose’ celecoxib and metronomic ‘low-dose’ cyclophosphamide and methotrexate in patients with relapsed and refractory lymphoma

INTRODUCTION: Relapsed histologically aggressive non-Hodgkin’s lymphoma (NHL) has a poor prognosis; relapsed patients who respond to second-line chemotherapy have a better outcome after BMT, while those who do not respond to second line or are unfit for BMT have a worse prognosis and new treatments...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Abdel-Bary, N, Hashem, T, Metwali, H, Abd el Ghany, A, Magied, HA, El-Herbeiny, M
Format: Artigo
Idioma:Inglês
Publicat: Cancer Intelligence 2009
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3223995/
https://ncbi.nlm.nih.gov/pubmed/22276009
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3332/ecancer.2009.144
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars